Embrace a Lifetime of Clarity with cGP PRo®

Support your brain today and embrace a lifetime of clarity. Your brain needs steady blood flow and strong cellular communication to stay sharp. But as we age, these systems begin to decline. The evidence is clear: blood flow slows and as a consequence, memory fades. And the body’s natural balance of the brain’s protective hormone - insulin-like growth factor (IGF 1), begins to shift. This is where cGP makes all the difference, helping restore the body’s ability to use IGF 1 effectively.

  1. PCT Published Patent Application WO/2023/113623
    Filed: December 2022
    Inventor: Dr Jian Guan
    ‍
    Assignee: The cGP Lab Ltd, New Zealand

    First PCT country to issue acceptance: Australia (Nov 2024)
    Australian patent application: 2022408967

    Australian accepted claims:
    WHAT IS CLAIMED IS:
    1. A method for ameliorating the effects of and/or treating peripheral neuropathy in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of cyclic Glycine Proline (cGP).
    2. The method as claimed in claim 1, wherein the peripheral neuropathy is type 2 diabetes-associated peripheral neuropathy.
    3. The method as claimed in claim 1 or claim 2, wherein the composition is formulated for oral administration.
    4. The method as claimed in any one of the preceding claims, wherein the composition is formulated as a pill, tablet, capsule, liquid, powder, micronized powder, gel, soft gel full of liquid and/or combinations thereof.
    5. The method as claimed in claim 4, wherein the micronized powder particle size is substantially between 1 to 1000 micron.
    6. The method as claimed in any one of the preceding claims, wherein the composition is administered to provide a therapeutically effective dose of cGP of at least between 10,000 to 100,000 ng (10-100 μg) as daily dose.
    7. The method as claimed in claim 6, wherein the composition is administered to provide a therapeutically effective dose of cGP of between 20-40 μg as daily dose.
    8. The method as claimed in any one of the preceding claims, wherein the cGP is derived from any animal, marine and/or fungal sources.
    9. The method as claimed in claim 8, wherein the sources comprise bovine, marine and bone collagen sources.
    10. The method as claimed in claim 8 or 9, wherein the cGP is formed by hydrolysation of collagen or gelatin proteins to form linear peptides with repeated sequences of hydrolysed proline-glycine, wherein cyclisation of the linear peptides leads to production of cGP.
    11. The method as claimed in any one of claims 8 to 10, wherein the cGP is formed by hydrolysation of bovine collagen powder, collagen marine skin powder, fish skin powder and/or bone collagen.
    12. The method as claimed in in any one of claims 8 to 10, wherein the cGP is formed from body parts selected from: skins, proteins, bones, muscles tendons and/or combinations thereof.
    13. The method as claimed in in any one of claims 8 to 10, wherein the cGP is formed by maceration of animal, marine and/or fungal material, followed by drying to forma micronized powder.
    14. The method as claimed in claim 13, wherein the micronized powder is encapsulated within soft gels and/or hard shells.
    15. The method as claimed in claim 14, wherein the soft gels and/or hard shells comprise gelatin.
    16. The method as claimed in claim 15, wherein the cGP concentration increases overtime.
    17. The method as claimed in claim 16, wherein the increase is from 0.1ng/mg to10ng/mg.

HOMEDR JIAN GUANDR GUAN'S PUBLICATIONSOUR BRANDSPATENTSHOW cGP WORKScGP-PRoCONTACT

The cGP Lab Ltd, COPYRIGHT 2023